BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update

BioLineRx (BLRX) Tops Q2 EPS by 69c

August 6, 2020 9:07 AM EDT

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.04), $0.69 better than the analyst estimate of ($0.73).

"We continue to eagerly await important survival data from the triple combination arm of our COMBAT/KEYNOTE-202 clinical trial of motixafortide in combination with KEYTRUDA and chemotherapy in metastatic pancreatic cancer," stated Philip Serlin, Chief Executive Officer of BioLineRx. "The compelling data on 22 patients that we reported in December give us conviction that this combination has the potential to be a real breakthrough in one of the most difficult to treat cancers. As this is an event-driven trial, we... More